Cancer Res Treat.  2021 Apr;53(2):355-366. 10.4143/crt.2020.847.

A Nationwide, Population-Based Epidemiology Study of Primary Central Nervous System Tumors in Korea, 2007-2016: A Comparison with United States Data

Affiliations
  • 1Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea
  • 2Department of Neurosurgery, Gangneung Asan Hospital, Gangneung, Korea
  • 3Division of Cancer Registration and Surveillance, National cancer center, Goyang, Korea
  • 4Department of Cancer Control and Population Health, National cancer center, Goyang, Korea
  • 5Neuro-Oncology clinic, National cancer center, Goyang, Korea

Abstract

Purpose
The purpose of this study was to determine the epidemiologic characteristics and survival of patients with primary brain and other central nervous system (CNS) tumors in Korea and to compare our findings with those from the United States.
Materials and Methods
We collected data on primary brain and CNS tumors diagnosed between 2007 and 2016 from the Korea Central Cancer Registry. The age-standardized incidence rates (ASRs) and 5-year relative survival rates (RSRs) were evaluated. We applied the classification and definitions of the Central Brain Tumor Registry of the United States to our analysis for direct comparison with United States data.
Results
A total of 115,050 primary brain and CNS tumors were identified, and the ASR of all tumors was 22.01 per 100,000 individuals, which was lower than the 23.41 in the United States. However, the ASR of malignant tumors was significantly lower herein (4.27) than in the United States (7.08). Meningeal tumors were the most common histologic group among all tumors (ASR, 8.32). The 5-year RSR of all primary brain and other CNS tumors was 86.4%, and that of all malignant tumors was 44.1%, which was higher than the 35.8% observed in the United States. Among malignant tumors, glioblastomas had the lowest 5-year RSR (12.1%).
Conclusion
In Korea, malignant brain and other CNS tumors have a lower incidence and better survival outcome.

Keyword

Epidemiology; Brain neoplasms; Incidence; Survival rate

Figure

  • Fig. 1 Comparison of incidence of primary brain and central nervous system tumors by age groups between Korea and the United States. Our data was from the KCCR, 2007–2016; U.S. data was from CBTRUS, 2012–2016. We standardized to U.S. 2000 population to directly compare our incidences to those of the United States. CB­TRUS, Central Brain Tumor Registry of the United States; KCCR, Korean Central Cancer Registry.

  • Fig. 2 Distribution of primary brain and other CNS tumors by location, sex and malignancy. (A) The distribution of all types of primary brain and other CNS tumors by location and behavior. (B) The distribution of all types of primary brain and other CNS tumors by location and sex. (C) Comparison of M:F rate ratio by histology between the United States and Korea. CBTRUS, Central Brain Tumor Registry of the United States; CNS, central nervous system; KCCR, Korean Central Cancer Registry; M:F rate ratio, male-to-female incidence rate ratio. *A statistically significant difference between sexes.

  • Fig. 3 Incidence trend of primary brain and other central nervous system tumors by behavior and age group. *A statistically significant annual percent changes (APC).


Cited by  1 articles

Anaplastic Meningioma: Clinical Characteristics, Prognostic Factors and Survival Outcome
Dong Ok Seo, Sang Woo Song, Young-Hoon Kim, Chang-Ki Hong, Jeong Hoon Kim
Brain Tumor Res Treat. 2022;10(4):244-254.    doi: 10.14791/btrt.2022.0030.


Reference

References

1. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International Classification of Diseases for Oncology (ICD-O). 3rd ed. Geneva: World Health Organization;2000.
2. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019; 21:v1–100.
Article
3. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975–2007. Bethesda, MD: National Cancer Institute;2010.
4. Lee CH, Jung KW, Yoo H, Park S, Lee SH. Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc. 2010; 48:145–52.
Article
5. Jung KW, Ha J, Lee SH, Won YJ, Yoo H. An updated nationwide epidemiology of primary brain tumors in republic of Korea. Brain Tumor Res Treat. 2013; 1:16–23.
Article
6. Dho YS, Jung KW, Ha J, Seo Y, Park CK, Won YJ, et al. An updated nationwide epidemiology of primary brain tumors in Republic of Korea, 2013. Brain Tumor Res Treat. 2017; 5:16–23.
Article
7. Jung KW, Won YJ, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat. 2019; 51:417–30.
Article
8. Korean Statistical Information Service [Internet]. Daejeon: Korean Statistics;2019. [cited 2020 Jan 10]. Available from: http://kosis.kr.
9. Kaneko S, Nomura K, Yoshimura T, Yamaguchi N. Trend of brain tumor incidence by histological subtypes in Japan: estimation from the Brain Tumor Registry of Japan, 1973–1993. J Neurooncol. 2002; 60:61–9.
10. Wohrer A, Waldhor T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mosenbacher U, et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009; 95:401–11.
Article
11. Sant M, Minicozzi P, Lagorio S, Borge Johannesen T, Marcos-Gragera R, Francisci S, et al. Survival of European patients with central nervous system tumors. Int J Cancer. 2012; 131:173–85.
Article
12. Jazayeri SB, Rahimi-Movaghar V, Shokraneh F, Saadat S, Ramezani R. Epidemiology of primary CNS tumors in Iran: a systematic review. Asian Pac J Cancer Prev. 2013; 14:3979–85.
Article
13. de Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St Germaine-Smith C, et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. 2015; 17:776–83.
Article
14. Chien LN, Gittleman H, Ostrom QT, Hung KS, Sloan AE, Hsieh YC, et al. Comparative brain and central nervous system tumor incidence and survival between the United States and Taiwan based on population-based registry. Front Public Health. 2016; 4:151.
Article
15. Miranda-Filho A, Pineros M, Soerjomataram I, Deltour I, Bray F. Cancers of the brain and CNS: global patterns and trends in incidence. Neuro Oncol. 2017; 19:270–80.
Article
16. Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daude H, et al. Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol. 2017; 131:525–46.
Article
17. Lin YJ, Chiu HY, Chiou MJ, Huang YC, Wei KC, Kuo CF, et al. Trends in the incidence of primary malignant brain tumors in Taiwan and correlation with comorbidities: a population-based study. Clin Neurol Neurosurg. 2017; 159:72–82.
Article
18. Pouchieu C, Gruber A, Berteaud E, Menegon P, Monteil P, Huchet A, et al. Increasing incidence of central nervous system (CNS) tumors (2000–2012): findings from a population based registry in Gironde (France). BMC Cancer. 2018; 18:653.
Article
19. Nakamura H, Makino K, Yano S, Kuratsu JI. Kumamoto Brain Tumor Research Group. Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto prefecture in southern Japan--20-year study. Int J Clin Oncol. 2011; 16:314–21.
Article
20. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424.
Article
21. Woehrer A, Hackl M, Waldhor T, Weis S, Pichler J, Olschowski A, et al. Relative survival of patients with non-malignant central nervous system tumours: a descriptive study by the Austrian Brain Tumour Registry. Br J Cancer. 2014; 110:286–96.
Article
22. Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54:78–93.
Article
23. Woehrer A. Brain tumour epidemiology in Austria and the Austrian brain tumour registry. Clin Neuropathol. 2013; 32:269–85.
24. Bruhn H, Strandeus M, Milos P, Hallbeck M, Vrethem M, Lind J. Improved survival of Swedish glioblastoma patients treated according to Stupp. Acta Neurol Scand. 2018; 138:332–7.
Article
25. Glied S, Jackson A. The future of the affordable care act and insurance coverage. Am J Public Health. 2017; 107:538–40.
Article
26. Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014; 23:1985–96.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr